Comparison of additive effect of omega-3 fatty acid or ezetimibe in combination with statins on the reduction of small dense LDL in patients with coronary artery disease

Trial Profile

Comparison of additive effect of omega-3 fatty acid or ezetimibe in combination with statins on the reduction of small dense LDL in patients with coronary artery disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2013

At a glance

  • Drugs Ezetimibe (Primary) ; Omega-3-fatty-acid (Primary) ; HMG-CoA reductase inhibitors
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top